Natalie Khuseyinova1, Wolfgang Koenig. 1. Department of Internal Medicine II - Cardiology, University of Ulm Medical Center, Ulm, Germany.
Abstract
PURPOSE OF REVIEW: Recognition of the fact that low-grade local and systemic inflammation accompanies all stages of atherogenesis has led to the identification of a number of novel biomarkers of cardiovascular risk. We highlight recent epidemiological and experimental evidence concerning four emerging biomarkers: C-reactive protein, interleukin-6, D-dimer and white blood cell count. RECENT FINDINGS: Recent epidemiological and experimental data on C-reactive protein, the most extensively studied marker of systemic inflammation, produced in the liver in response to interleukin-6, has cast some doubt on its clinical utility and causal involvement in atherogenesis. However, a large number of studies still strongly support C-reactive protein as an independent predictor of future cardiovascular risk and a potent proatherogenic agent. Among all markers of inflammation studied to date, C-reactive protein seems the most suitable one for use in clinical practice. Regarding white blood cell count, recent studies focused on the differential leucocyte count in coronary-heart-disease risk assessment; neutrophil count represents the strongest predictor of incident coronary heart disease. SUMMARY: Thus, screening for low-grade inflammation using several novel biomarkers might provide an important tool to identify individuals at increased risk who would benefit most from targeted preventive interventions.
PURPOSE OF REVIEW: Recognition of the fact that low-grade local and systemic inflammation accompanies all stages of atherogenesis has led to the identification of a number of novel biomarkers of cardiovascular risk. We highlight recent epidemiological and experimental evidence concerning four emerging biomarkers: C-reactive protein, interleukin-6, D-dimer and white blood cell count. RECENT FINDINGS: Recent epidemiological and experimental data on C-reactive protein, the most extensively studied marker of systemic inflammation, produced in the liver in response to interleukin-6, has cast some doubt on its clinical utility and causal involvement in atherogenesis. However, a large number of studies still strongly support C-reactive protein as an independent predictor of future cardiovascular risk and a potent proatherogenic agent. Among all markers of inflammation studied to date, C-reactive protein seems the most suitable one for use in clinical practice. Regarding white blood cell count, recent studies focused on the differential leucocyte count in coronary-heart-disease risk assessment; neutrophil count represents the strongest predictor of incident coronary heart disease. SUMMARY: Thus, screening for low-grade inflammation using several novel biomarkers might provide an important tool to identify individuals at increased risk who would benefit most from targeted preventive interventions.
Authors: Tracy E Crane; Chieri Kubota; Julie L West; Mark A Kroggel; Betsy C Wertheim; Cynthia A Thomson Journal: J Nutr Date: 2011-08-24 Impact factor: 4.798
Authors: Karin F Hoth; Andreana P Haley; John Gunstad; Robert H Paul; Athena Poppas; Angela L Jefferson; David F Tate; Makoto Ono; Beth A Jerskey; Ronald A Cohen Journal: J Am Geriatr Soc Date: 2008-09-02 Impact factor: 5.562
Authors: Suzan Wopereis; Carina M Rubingh; Marjan J van Erk; Elwin R Verheij; Trinette van Vliet; Nicole H P Cnubben; Age K Smilde; Jan van der Greef; Ben van Ommen; Henk F J Hendriks Journal: PLoS One Date: 2009-02-26 Impact factor: 3.240
Authors: D H Watts; M Lu; B Thompson; R E Tuomala; W A Meyer; H Mendez; K Rich; C Hanson; P LaRussa; C Diaz; L M Mofenson Journal: Infect Dis Obstet Gynecol Date: 2009-11-02